Louise M. Arnold

Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?

Journal: Annals of hematology
Published: February 24, 2025

First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria.

First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria.

Journal: British journal of haematology
Published: December 17, 2024

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Journal: British journal of haematology
Published: November 12, 2024

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

Journal: Blood advances
Published: July 08, 2024

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Journal: Blood
Published: July 07, 2023

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

Journal: Blood
Published: May 31, 2022

COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria.

COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria.

Journal: The Lancet. Haematology
Published: March 21, 2022

The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018.

The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018.

Journal: European journal of haematology
Published: March 05, 2021

COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.

COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.

Journal: British journal of haematology
Published: August 14, 2020

Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry.

Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry.

Journal: British journal of haematology
Published: September 09, 2019

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.

Journal: Haematologica
Published: March 21, 2019

Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Journal: Haematologica
Published: October 06, 2018
Showing 1-12 of 14

Last Updated: 09/26/2026